{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:42:37Z","timestamp":1790995357388,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study evaluated the efficacy and safety of baricitinib (Janus kinase-1\/2 inhibitor), in adult and pediatric Japanese patients with Nakajo-Nishimura syndrome\/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS\/CANDLE), stimulator of interferon genes-associated vasculopathy with onset during infancy (SAVI), or Aicardi-Gouti\u00e8res syndrome (AGS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Phase 2\/3, multicenter, open-label study (NCT04517253) was conducted across 52\u00a0weeks. Primary efficacy endpoint assessed the change in mean daily diary score (DDS) from baseline to the end of primary treatment period. Other efficacy endpoints included change in mean DDS to the end of maintenance period, daily corticosteroid use, Physician\u2019s Global Assessment of Disease Activity (PGA) scores, and daily symptom-specific score (DSSS) from baseline to primary and maintenance treatment periods. All treatment-emergent adverse events (TEAEs) that occurred postdosing were recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 9 patients (5 with NNS, 3 with SAVI, and 1 with AGS) were enrolled; 55.6% were females, mean age was 26\u00a0years, and mean corticosteroid use\/weight was 0.2\u00a0mg\/kg. At the end of primary treatment period, mean DDS decreased from baseline in patients with NNS\/CANDLE (0.22) and SAVI (0.21) and increased in the patient with AGS (0.07). At the end of maintenance treatment period, mean DDS decreased from baseline in patients with NNS\/CANDLE (0.18) and SAVI (0.27) and increased in the patient with AGS (0.04). Mean percent corticosteroid use decreased by 18.4% in 3 out of 5 patients with NNS\/CANDLE and 62.9% in 1 out of 3 patients with SAVI. Mean PGA score decreased from baseline in patients with NNS\/CANDLE (1.60), SAVI (1.33), and AGS (1.0), and mean DSSS improved from baseline. All patients reported\u2009\u2265\u20091 TEAE. Frequently reported AEs included BK polyomavirus detection (3; 33.3%), increased blood creatine phosphokinase (2; 22.2%), anemia (2; 22.2%), and upper respiratory tract infection (2; 22.2%). Three (33.3%) patients reported serious adverse events, 1 of which was related to study drug. One patient with SAVI died due to intracranial hemorrhage, which was not related to study drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Baricitinib may offer a potential therapeutic option for patients with NNS\/CANDLE, SAVI, and AGS, with a positive benefit\/risk profile in a vulnerable patient population with multiple comorbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NLM clinicaltrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04517253\">NCT04517253<\/jats:ext-link>. Registered 18 August 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00817-8","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T15:01:49Z","timestamp":1682175709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS\/CANDLE, SAVI, And AGS)"],"prefix":"10.1186","volume":"21","author":[{"given":"Nobuo","family":"Kanazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Nishikomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"issue":"10","key":"817_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","volume":"94","author":"H Kim","year":"2016","unstructured":"Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS. Monogenic Lupus J Mol Med (Berl). 2016;94(10):1111\u201327.","journal-title":"Monogenic Lupus J Mol Med (Berl)"},{"issue":"2","key":"817_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3329\/jbcps.v40i2.58697","volume":"40","author":"NAS Liza","year":"2022","unstructured":"Liza NAS, Anwar SS, Kundu GK. Aicardi-Goutieres syndrome-a case report. J Bangladesh CollPhys Surgeons. 2022;40(2):132\u20135.","journal-title":"J Bangladesh CollPhys Surgeons"},{"issue":"36","key":"817_CR3","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1073\/pnas.1106015108","volume":"108","author":"K Arima","year":"2011","unstructured":"Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A. 2011;108(36):14914\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"817_CR4","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1172\/JCI81260","volume":"125","author":"A Brehm","year":"2015","unstructured":"Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, et al. Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production. J Clin Invest. 2015;125(11):4196\u2013211.","journal-title":"J Clin Invest"},{"issue":"3","key":"817_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","volume":"64","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012;64(3):895\u2013907.","journal-title":"Arthritis Rheum"},{"key":"817_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/978-1-4614-8678-7_129","volume-title":"Encyclopedia of medical immunology: immunodeficiency diseases","author":"GA Montealegre Sanchez","year":"2020","unstructured":"Montealegre Sanchez GA, de Jesus AA, Goldbach-Mansky R. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE)\/proteasome-associated autoinflammatory syndromes (PRAAS). In: Orange JS, Chinen J, editors. Encyclopedia of medical immunology: immunodeficiency diseases. New York: Springer, New York; 2020. p. 156\u201361."},{"issue":"2","key":"817_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","volume":"76","author":"N K\u00f6nig","year":"2017","unstructured":"K\u00f6nig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, T\u00fcngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"817_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"817_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajmg.a.36887","volume":"167","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167(2):296\u2013312.","journal-title":"Am J Med Genet A"},{"key":"817_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/bmb\/ldn049","volume":"89","author":"S Orcesi","year":"2009","unstructured":"Orcesi S, La Piana R, Fazzi E. Aicardi-Goutieres syndrome. Br Med Bull. 2009;89:183\u2013201.","journal-title":"Br Med Bull"},{"issue":"7","key":"817_CR11","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352.","journal-title":"J Clin Invest"},{"issue":"1","key":"817_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12115","volume":"175","author":"YJ Crow","year":"2014","unstructured":"Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI. Therapies in Aicardi-Gouti\u00e8res syndrome. Clin Exp Immunol. 2014;175(1):1\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"817_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/PL00000267","volume":"50","author":"P Igaz","year":"2001","unstructured":"Igaz P, T\u00f3th S, Falus A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res. 2001;50(9):435\u201341.","journal-title":"Inflamm Res"},{"key":"817_CR14","unstructured":"Baricitnib FDA label. https:\/\/www.pmda.go.jp\/files\/000243207.pdf. Accessed 3 June 2022."},{"key":"817_CR15","unstructured":"Baricitinib Pharmaceutical and Medical Devices Agency. https:\/\/www.pmda.go.jp\/files\/000243207.pdf. Accessed 3 June 2022."},{"issue":"2","key":"817_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","volume":"104","author":"H Kim","year":"2018","unstructured":"Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104(2):364\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"817_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, et al. Janus Kinase Inhibition in the Aicardi-Gouti\u00e8res Syndrome. N Engl J Med. 2020;383(10):986\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"817_CR18","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3899\/jrheum.091474","volume":"37","author":"G Filocamo","year":"2010","unstructured":"Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37(7):1534\u201341.","journal-title":"J Rheumatol"},{"key":"817_CR19","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Md State Med J. 1965;14:61\u20135.","journal-title":"Md State Med J"},{"issue":"2","key":"817_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0092-8674(93)90415-M","volume":"74","author":"LS Argetsinger","year":"1993","unstructured":"Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 1993;74(2):237\u201344.","journal-title":"Cell"},{"issue":"2","key":"817_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz P-Y, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333\u201340.","journal-title":"Ann Rheum Dis"},{"key":"817_CR22","unstructured":"Gedik KC, Adeva GS, Wade J, Sanchez GM, de Jesus A, Goldbach-Mansky R, editors. Monitoring of BK Reactivation and Long-term Safety on JAK1\/2 Inhibition with Baricitinib. Arthritis Rheumatol.\u00a0Hoboken: Wiley;\u00a02020."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00817-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T15:02:07Z","timestamp":1682175727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00817-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]},"assertion":[{"value":"10 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the institutional review boards prior to patient recruitment, and each patient provided written informed consent prior to enrollment. The study was conducted in accordance with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and the International Ethical Guidelines by the Council for International Organizations of Medical Sciences and the International Council for Harmonisation E6 Guidelines for Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Taeko Ishii, Yasushi Takita, and Atushi Nishikawa are Lilly\u2019s employees and shareholders of Eli Lilly and Company. Nobuo Kanazawa and Ryuta Nishikomori have no conflicting interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}